Biogen
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Recent Developments in Biosimilars: Legal Settlements, Launches, and Legislative Efforts
Recent developments in biosimilars include Biocon Biologics and Sandoz launching biosimilar competitors, legal settlements affecting biosimilar launches, and legislative efforts to increase biosimilar access. Key events involve adalimumab, ustekinumab, and aflibercept biosimilars, with companies like Amgen, Johnson & Johnson, and Regeneron at the center of legal and market activities.
Research Clinical Trials: Hosting Studies on Neurosurgery Treatments and Technologies
Hosting clinical trials for new treatments and tech in neurosurgery, including studies on spinal cord injuries, brain injuries, Alzheimer’s, and chronic pain, with collaborations from major hospitals and institutions.
The Concept of Biosimilars: From Characterization to Market Impact
Biosimilars, similar to biologics in safety and efficacy, face complex production challenges. Regulatory frameworks vary globally, with the EU leading in biosimilar approvals. Biosimilars offer cost savings, with significant market growth expected as biologics' patents expire. The U.S. and EU are key markets, with biosimilars projected to save billions in healthcare costs.
© Copyright 2025. All Rights Reserved by MedPath